Evidence map›Paper›PMID 37737650›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma.

Madhav V Dhodapkar

Open access · greenAbstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Madhav V DhodapkarDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.ORCID 0000-0002-8249-5988
Emory University · US

Funding

HARNESSING HOST RESPONSE TO PREVENT MYELOMAR35CA197603 · NCI · YALE UNIVERSITY · PI DHODAPKAR, MADHAV V · 2016 to 2022
$5.8M
NCI NIH HHS R35 CA197603
6 · The paper itself

Abstract

Immune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 4575.

Indexed as

Cancer VaccinesMultiple MyelomaDendritic CellsHumansT-LymphocytesCancer Vaccines

Identifiers

PMID37737650
PMCPMC10873105
OpenAlexW4386944718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.